CA2937315A1 — Tablet formulation for cgrp-active compounds
Assigned to Merck Sharp and Dohme LLC · Expires 2015-08-13 · 11y expired
What this patent protects
The present invention is directed to compositions comprising an extrudate or solid solution of a compound, or a salt thereof, of Formula I (API): Formula I, wherein "Ra" is independently H or -F, in a water-soluble polymer matrix which further comprises a disintegration s…
USPTO Abstract
The present invention is directed to compositions comprising an extrudate or solid solution of a compound, or a salt thereof, of Formula I (API): Formula I, wherein "Ra" is independently H or -F, in a water-soluble polymer matrix which further comprises a disintegration system allowing a tablet made therefrom to rapidly disintegrate in the environment in which the API is to be released.
Drugs covered by this patent
- Ubrelvy (UBROGEPANT) · AbbVie
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.